logo
A Construction Crew Accidentally Uncovered the Remains of 100+ Horses

A Construction Crew Accidentally Uncovered the Remains of 100+ Horses

Yahoo28-04-2025

Crews working on a housing project in the Bad Cannstatt district of Stuttgart recently uncovered a second-century horse cemetery.
Archaeologists discovered over 100 skeletons of horses used by the Roman calvary.
The site was a known military stronghold for the Roman army.
A well-defined horse cemetery uncovered in Stuttgart's Bad Cannstatt neighborhood was the final resting place for over 100 horses that were part of the Roman Empire's cavalry in the second century A.D.
Construction crews discovered the cemetery during preparations for a housing project. Over time, excavations by the archaeological company ArchaeoBW—under the supervision of the State Office for Monument Preservation of the Stuttgart Regional Council—continued to unearth evidence from what is now believed to be the largest Roman-era horse cemetery in southern Germany, according to a translated statement from the council.
Considered one of the most important Roman military locations in modern-day southwestern Germany, experts believe the Roman calvary occupying the region had about 500 soldiers on site, and sustained a potential population of over 700 horses.
The first discovery of a horse skeleton in the area actually occurred in 1920 (also during a housing project), but the recent development uncovered the entire cemetery. Sara Roth, an archaeologist with the preservation office, said that radiocarbon dating helped pinpoint the age of the cemetery. 'Due to the archaeological and historical knowledge of the Roman Bad Cannstatt,' she said in a statement, 'the horses of the equestrian unit—a so-called ala—can be assigned, which was stationed on the Hallschlag from about 100 to 150 A.D.'
Roth said that the deceased horses were buried about 1,300 feet from the equestrian barns (about 650 feet from the soldier's quarters), and would have been constantly replaced. Evidence shows that the carcasses were slid into shallow pits and buried lying on their side with outstretched or bent legs. And even with the dense burials, there were few overlaps of graves, exposing that the site was likely clearly defined with above-ground markers. Even if a horse could walk on its own, if it was deemed beyond military usefulness, it would have been taken to the cemetery and killed there.
'The horses do not seem to have all died at the same time in a major event such as a battle or epidemic,' Roth said. 'Rather, here are the animals that either died during the presence of the ala in Bad Cannstatt due to illness, injury, or other reasons, or who no longer did their task as a military horse.'
One grave was of particular interest to archaeologists, as they discovered two jugs and a small oil lamp placed in the crook of the legs of one of the horses—grave goods typically reserved for humans. 'Here we see a particularly close connection of the owner to his horse,' Roth said. 'Even after about 1,800 years, the grief over the death of this one animal is still apparent.'
The crew also discovered the face-down skeleton of a human male—far from the regular burial location for the Roman settlement, he was likely a social outcast.
Experts plan to study the sex, age at death, and size of the horses while looking for possible diseases and causes of death. The team hopes to uncover more details about the Roman calvary.
You Might Also Like
The Do's and Don'ts of Using Painter's Tape
The Best Portable BBQ Grills for Cooking Anywhere
Can a Smart Watch Prolong Your Life?

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Is it true that … cold water plunges boost immunity?
Is it true that … cold water plunges boost immunity?

Yahoo

time2 hours ago

  • Yahoo

Is it true that … cold water plunges boost immunity?

'It's a long-held belief that taking to the waters is good for your health,' says Mike Tipton, a professor of human and applied physiology at the University of Portsmouth. From Roman frigidariums to Thomas Jefferson's foot baths, cold immersion has long been seen as curative. But does modern science support the idea that it boosts immunity? The answer: it's complicated. While cold water immersion does activate the body, that's not the same as strengthening the immune system. 'When you immerse yourself in cold water, your body undergoes the cold shock response,' says Tipton. 'You get rapid breathing, a spike in heart rate and a surge of stress hormones such as adrenaline and cortisol.' This may explain why people feel more alert or energised after a cold dip. But does it mean you're less likely to get sick? Many studies into the effects focus on immune cell activity in the blood – which can increase after cold exposure – but that doesn't always translate into fewer infections. 'It's easy to cherry-pick results,' says Tipton. He points to a frequently quoted Dutch study in which people who ended their daily hot showers with at least 30 seconds under cold water took 29% fewer sick days. While it's often used as an example of the powers of cold plunges, those participants actually reported the same number of infections as those who didn't have a cold shower. 'That might reflect increased resilience or just a willingness to push through because of being part of a study,' says Tipton, rather than better immunity. It may also be that regular cold plungers simply have a healthier lifestyle overall. A recent study by Tipton's team found that indoor and outdoor swimmers had fewer respiratory infections than non-swimmers, suggesting it may be the exercise, not the cold, doing the work. One thing is clear: too much cold is harmful. 'If your core temperature drops too far, it can suppress the immune system,' he says. His advice? Keep it short – no more than 90 seconds.

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

Yahoo

time3 hours ago

  • Yahoo

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

SAN FRANCISCO and VANCOUVER, British Columbia, June 09, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ('Jade') (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced a detailed preclinical characterization of JADE101, its anti-A Proliferation-Inducing Ligand (APRIL) monoclonal antibody, in development for IgA nephropathy (IgAN), a chronic autoimmune kidney disease. The findings, presented during an oral session at the 62nd European Renal Association (ERA) Congress, support advancement of JADE101 into a planned healthy volunteer study in the second half of 2025. 'IgA nephropathy often begins in young adulthood and typically requires lifelong treatment, yet current treatment options have limitations in efficacy and ease of use,' said Andrew King, BVMS, Ph.D., Chief Scientific Officer and Head of R&D at Jade Biosciences. 'Jade's preclinical data presented at ERA demonstrate JADE101's potential to be a best-in-class disease-modifying therapy. JADE101 has the potential to fully capture the efficacy available to the anti-APRIL mechanism with convenient, infrequent dosing. We believe this profile could translate into meaningful long-term benefit for patients, and we look forward to advancing this promising candidate into the clinic later this year.' Summary of Jade Biosciences' ERA 2025 Presentation Jade's presentation at ERA focused on a comprehensive preclinical characterization of JADE101, a fully human monoclonal antibody targeting APRIL, designed to address key limitations of earlier molecules in this class. JADE101 incorporates a YTE-modified IgG1 backbone and was engineered to improve target affinity, extend pharmacokinetic exposure, and reduce risks associated with immune complex formation and rapid clearance. The molecular design of JADE101 prolonged systemic exposure that delivers sustained target engagement, with a goal of supporting clinical dosing intervals of eight weeks or potentially longer. JADE101 was compared with sibeprenlimab, an investigational late-stage anti-APRIL monoclonal antibody, manufactured from publicly available sequences. A YTE-engineered version of sibeprenlimab was also tested to isolate the impact of Fc modification on pharmacokinetic profiles in non-human primates (NHPs). Key findings included: Ultra-high APRIL binding affinityJADE101 binds APRIL with femtomolar affinity (approximately 50 fM), over 750-fold higher affinity than sibeprenlimab. This higher binding affinity has the potential to enable complete suppression of APRIL at low plasma concentrations of JADE101 to deliver the full efficacy available to the anti-APRIL mechanism and further support an extended dosing interval. Potent inhibition of APRIL signaling through BCMA and TACIJADE101 demonstrated potent blockade of APRIL binding and signaling through its receptors in in vitro assays, including assays designed to model mechanistic aspects of the therapeutic benefit of APRIL inhibition in IgAN. In competitive binding assays, JADE101 fully inhibited APRIL binding to its receptors BCMA and TACI with IC50 values of 1.9 nM and 1.03 nM, respectively. In cell-based reporter assays, JADE101 blocked APRIL-induced signaling through BCMA (IC50 = 5.97 nM) and TACI (IC50 = 0.22 nM). JADE101 also potently reduced human plasma cell proliferation and IgA secretion in vitro. Extended pharmacokinetics and deep, sustained IgA suppression in NHPsIn NHPs, a single 30 mg/kg intravenous dose of JADE101 demonstrated an approximately 27-day half-life, nearly 4 times longer than sibeprenlimab at the same dose, and maintained linear clearance down to approximately 2 µg/mL, well below the approximately 40 µg/mL target-mediated drug disposition (TMDD) threshold observed for sibeprenlimab. This pharmacokinetic profile translated into sustained IgA suppression for more than 100 days after a single 30 mg/kg dose in NHPs. Notably, JADE101 dosed at just 4 mg/kg (7.5-fold lower) achieved deeper and more durable IgA reductions in NHPs than both sibeprenlimab and YTE-modified sibeprenlimab dosed at 30 mg/kg. Favorable subcutaneous profile in NHPsFollowing a single 100 mg/kg subcutaneous dose, JADE101 exhibited high bioavailability and a linear half-life exceeding 30 days in NHPs, supporting the potential for convenient, infrequent subcutaneous dosing in clinical settings. Designed to reduce risk of high molecular weight immune complex formationJADE101 binds a novel epitope on trimeric APRIL and was specifically selected to avoid the formation of high molecular weight immune complexes, that can occur with the first-generation anti-APRIL monoclonal antibodies. Immune complexes have potential to be associated with an increased risk of immunogenicity and tissue deposition, and to result in accelerated drug clearance. By avoiding their formation, JADE101 may mitigate these risks, supporting more consistent pharmacokinetics and sustained exposure over time. Jade plans to initiate a study of JADE101 in healthy volunteers in the second half of 2025. The study will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and suppression of key biomarkers including APRIL and IgA. Interim data are expected in the first half of 2026 and are anticipated to guide dose and dose interval selection for future JADE101 studies in patients with IgAN. Conference Call and Webcast Jade Biosciences will host a conference call and webcast today, Monday, June 9, 2025, at 8:00 a.m. ET to review the JADE101 data presented at ERA 2025. Investors and the public are invited to join the live webcast by registering on the 'Events and Presentations' page of To join the conference call, participants must register here. Upon registering, dial-in details and a unique PIN will be provided. A replay of the webcast will be available shortly after the call concludes. About IgA nephropathy (IgAN) IgAN is a chronic autoimmune kidney disease that affects approximately 169,000 people in the U.S. and is most often diagnosed in young adults. The disease is characterized by the deposition of pathogenic IgA-containing immune complexes in the kidneys. These deposits can lead to increased protein in the urine, also known as proteinuria, declining kidney function, and potentially end-stage kidney disease requiring dialysis or a transplant. IgAN often requires lifelong treatment to preserve kidney function and prevent progression to kidney failure. About JADE101 JADE101 is an anti-APRIL monoclonal antibody being developed for the treatment of IgAN. By targeting APRIL, a protein involved in the overproduction of IgA, JADE101 aims to reduce the levels of disease-driving IgA, decrease proteinuria, and preserve kidney function. Engineered with half-life extension technology, JADE101 is designed for dosing at intervals of at least eight weeks, offering the potential for durable clinical activity and improved patient convenience, particularly important for a condition often diagnosed in young adulthood and potentially requiring life-long treatment. About Jade Biosciences, Inc. Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead candidate, JADE101, targets the cytokine APRIL for the treatment of immunoglobulin A nephropathy, with initiation of a first-in-human clinical trial expected in the second half of 2025. Jade's pipeline also includes a second development candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit and follow the Company on LinkedIn. Forward-Looking Statements Certain statements in this communication, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Jade's expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, Jade's ability to achieve the expected benefits or opportunities with respect to JADE101, JADE201 and the JADE-003 program, including without limitation the expected timelines for JADE101 entering the clinic and interim data from such trial, the potential of Jade's product candidates to become best-in-class therapies and their potential therapeutic uses, efficacy, dosing, safety and market opportunities. The words "opportunity," "potential," "milestones," "pipeline," "can," "goal," "strategy," "target," "anticipate," "achieve," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "plan," "possible," "project," "should," "will," "would" and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Jade will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the planned trial of JADE101 and any future clinical trials may be delayed or may not demonstrate safety and/or efficacy; Jade may experience unanticipated costs, difficulties or delays in the product development process; Jade's product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; risks associated with Jade's dependence on third-party vendors for the development, manufacture and supply of JADE101; and the other risks, uncertainties and factors more fully described in Jade's most recent filings with the Securities and Exchange Commission (including the definitive proxy statement/prospectus filed on Form S-4, most recently amended on March 24, 2025 and declared effective on March 25, 2025). Should one or more of these risks or uncertainties materialize, or should any of Jade's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade. Jade Biosciences Media & Investor Contacts Priyanka ShahEmail: Media@ Email: IR@ Phone: 908-447-6134登入存取你的投資組合

Archaeologists Find Grisly Evidence of Medieval Public Punishment
Archaeologists Find Grisly Evidence of Medieval Public Punishment

Yahoo

time2 days ago

  • Yahoo

Archaeologists Find Grisly Evidence of Medieval Public Punishment

Archaeologists in England have uncovered gruesome evidence of a Medieval-era public punishment which occurred along the River Thames more than 1,200 years ago, according to a new study (via Ancient Origins). Researchers conducted a full bioarchaeological analysis on the remains of a woman, known as UPT90 sk 1278, who had been beaten to death and was originally unearthed in 1991. "The burial treatment of UPT90 sk 1278 lets us know that her body was meant to be visible on the landscape, which could be interpreted as a warning to witnesses," said the study's lead author, Madeline Mant. "We can tell from the osteobiography that she was executed, but the specific offense is impossible to know for certain.'Mant and her team found that, as opposed to traditional burials of the time, the woman's body was not buried but left out in the open to decompose, likely as a warning to other residents of the community. Her body was placed in an area between the river and the shore, which would ensure her corpse would be alternately revealed and hidden by the tides. This was a location frequently chosen for those found to be 'socially deviant.' She had been placed between two sheets of bark on top of a reed mat with pads of moss affixed to areas on her face, which Mant believed to be symbolic gestures from her analysis revealed the woman, aged between 28 and 40 at the time of her death, had suffered 'dietary distress' at some point in her life, which the researchers believe to be related to childhood starvation or a drastic shift in diet. There were also signs that she had suffered as many as 50 'traumatic' injuries during two instances of violence which preceded her death, leaving her with blunt-force injuries to the torso and skull as well as a bilateral scapular fracture, which is often seen in car accident victims. Mant believes the woman endured a particularly grisly death because rules surrounding crime and punishment were extremely nebulous during this period. "As time passed, more crimes were associated with the death penalty,' she explained. 'This was a time of legal evolution."Archaeologists Find Grisly Evidence of Medieval Public Punishment first appeared on Men's Journal on Jun 7, 2025

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store